LIN7C

Across TCGA pan-cancer cohorts, LIN7C mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LIN7C’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LIN7C mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LIN7C is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where LIN7C tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LIN7C mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.717	<.001	12	view →
PDAC	Female	II,III,IV	−0.573	<.001	8	view →
HNSC	All	All	−0.235	<.001	8	view →
LSCC	Male	All	+0.125	<.001	5	view →
LUAD	Female	All	+0.093	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LIN7C–CCRCC

Open the CCRCC breakdown →